SHR-1918 clinical trials
Also written SHR-1918.
How each study uses SHR-1918 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SHR-1918 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SHR-1918
- 6
Studies by the year they started
8 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Beijing Suncadia Pharmaceuticals Co., Ltd (7) · Fujian Shengdi Pharmaceutical Co., Ltd. (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test SHR-1918, phase 3 first.
- Oct 2027A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With HyperlipidemiaPhase 3 · Beijing Suncadia Pharmaceuticals Co., Ltd
- Jun 2027Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute PancreatitisPhase 2 · Fujian Shengdi Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses SHR-1918 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With HyperlipidemiaRecruitingPhase 3Beijing Suncadia Pharmaceuticals Co., LtdNCT07230730Written as SHR-1918
- A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 InhibitorsRecruitingPhase 2/3Beijing Suncadia Pharmaceuticals Co., LtdNCT07404553Written as SHR-1918 Injection
- Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial HypercholesterolemiaNot yet recruitingPhase 2Beijing Suncadia Pharmaceuticals Co., LtdNCT07133815Written as SHR-1918
- Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute PancreatitisActive, not recruitingPhase 2Fujian Shengdi Pharmaceutical Co., Ltd.NCT07308392Written as SHR-1918 injection set
- Evaluate the Efficacy and Safety of SHR-1918 in Patients With HyperlipidemicCompletedPhase 2Beijing Suncadia Pharmaceuticals Co., LtdNCT06109831Written as SHR-1918
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial HypercholesterolemiaCompletedPhase 3Beijing Suncadia Pharmaceuticals Co., LtdNCT06723652Written as SHR-1918
- Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial HypercholesterolemiaCompletedPhase 2Beijing Suncadia Pharmaceuticals Co., LtdNCT06009393Written as SHR-1918
- Safety and Tolerability of SHR-1918 in Healthy SubjectsActive, not recruitingPhase 1Beijing Suncadia Pharmaceuticals Co., LtdNCT05432544Written as SHR-1918